CA2818428A1 - Tests et biomarqueurs destines au lrrk2 - Google Patents

Tests et biomarqueurs destines au lrrk2 Download PDF

Info

Publication number
CA2818428A1
CA2818428A1 CA2818428A CA2818428A CA2818428A1 CA 2818428 A1 CA2818428 A1 CA 2818428A1 CA 2818428 A CA2818428 A CA 2818428A CA 2818428 A CA2818428 A CA 2818428A CA 2818428 A1 CA2818428 A1 CA 2818428A1
Authority
CA
Canada
Prior art keywords
6alkyl
methyl
formula
certain embodiments
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2818428A
Other languages
English (en)
Inventor
Daisy Bustos
Donald Kirkpatrick
Tracy Kleinheinz
John Moffat
Zejuan Sheng
Shuo ZHANG
Haitao Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2818428A1 publication Critical patent/CA2818428A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
CA2818428A 2010-11-30 2011-11-29 Tests et biomarqueurs destines au lrrk2 Abandoned CA2818428A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41820810P 2010-11-30 2010-11-30
US61/418,208 2010-11-30
PCT/US2011/062468 WO2012075046A1 (fr) 2010-11-30 2011-11-29 Tests et biomarqueurs destinés au lrrk2

Publications (1)

Publication Number Publication Date
CA2818428A1 true CA2818428A1 (fr) 2012-06-07

Family

ID=45217723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2818428A Abandoned CA2818428A1 (fr) 2010-11-30 2011-11-29 Tests et biomarqueurs destines au lrrk2

Country Status (9)

Country Link
EP (1) EP2646819A1 (fr)
JP (1) JP2014504362A (fr)
KR (1) KR20130121903A (fr)
CN (1) CN103348243A (fr)
BR (1) BR112013013457A2 (fr)
CA (1) CA2818428A1 (fr)
MX (1) MX2013005801A (fr)
RU (1) RU2013129818A (fr)
WO (1) WO2012075046A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255049A1 (fr) 2012-06-29 2017-12-13 Pfizer Inc Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2
WO2014059052A1 (fr) * 2012-10-09 2014-04-17 Uab Research Foundation Méthodes et compositions destinées au diagnostic et au traitement de la maladie de parkinson et au parkinsonisme
US9582909B2 (en) * 2012-11-15 2017-02-28 Shimadzu Corporation Chromatograph mass spectrometry data processing device
WO2017156493A1 (fr) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Composés, compositions et procédés
WO2015092592A1 (fr) 2013-12-17 2015-06-25 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN105331721A (zh) * 2015-11-27 2016-02-17 首都医科大学宣武医院 检测pd致病基因突变的方法，及其引物、试剂盒
PE20240221A1 (es) 2016-06-16 2024-02-16 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CN111372576A (zh) 2017-11-17 2020-07-03 塞尔利克斯生物私人有限公司 用于治疗眼部病症的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007261095A1 (en) 2006-06-20 2007-12-27 Novartis Ag Biomarkers for the progression of Alzheimer's disease
WO2008091799A2 (fr) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Procédés basés sur des cellules, destinés à identifier des inhibiteurs de mutants lrrk2 associés à la maladie de parkinson
GB0706709D0 (en) * 2007-04-05 2007-05-16 Medical Res Council Methods
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
CA2760794C (fr) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Inhibiteurs d'egfr et procedes de traitement de troubles
US8367349B2 (en) * 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2

Also Published As

Publication number Publication date
BR112013013457A2 (pt) 2017-07-11
WO2012075046A9 (fr) 2012-09-13
MX2013005801A (es) 2013-07-17
JP2014504362A (ja) 2014-02-20
CN103348243A (zh) 2013-10-09
WO2012075046A1 (fr) 2012-06-07
KR20130121903A (ko) 2013-11-06
EP2646819A1 (fr) 2013-10-09
RU2013129818A (ru) 2015-01-10

Similar Documents

Publication Publication Date Title
CA2818428A1 (fr) Tests et biomarqueurs destines au lrrk2
Tang et al. Structure-guided mutagenesis reveals a hierarchical mechanism of Parkin activation
Chen et al. Aggregation of the nucleic acid–binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation
Braun et al. Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly
Sivadasan et al. C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons
Chou et al. GSK3beta-mediated Drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress
Zhang et al. Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the γTuRC to the centrosome
Lince-Faria et al. Spatiotemporal control of mitosis by the conserved spindle matrix protein Megator
Ivankovic-Dikic et al. Pyk2 and FAK regulate neurite outgrowth induced by growth factors and integrins
Balestrini et al. GEMC1 is a TopBP1-interacting protein required for chromosomal DNA replication
Xiong et al. GTPase activity plays a key role in the pathobiology of LRRK2
Solc et al. Multiple requirements of PLK1 during mouse oocyte maturation
DeLuca et al. Temporal changes in Hec1 phosphorylation control kinetochore–microtubule attachment stability during mitosis
Yoon et al. Homer1 promotes dendritic spine growth through ankyrin-G and its loss reshapes the synaptic proteome
Guo et al. CENP-E–dependent BubR1 autophosphorylation enhances chromosome alignment and the mitotic checkpoint
Tang et al. Netrin-1 mediates neuronal survival through PIKE-L interaction with the dependence receptor UNC5B
Penmatsa et al. Compartmentalized cyclic adenosine 3′, 5′-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains
Bentley et al. Distinct sequence elements of cyclin B1 promote localization to chromatin, centrosomes, and kinetochores during mitosis
Carvalhal et al. The nucleoporin ALADIN regulates Aurora A localization to ensure robust mitotic spindle formation
Ehlén et al. Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1
Song et al. Dynamic crotonylation of EB1 by TIP60 ensures accurate spindle positioning in mitosis
K Bhosle et al. Nuclear localization of platelet-activating factor receptor controls retinal neovascularization
Sana et al. Plk1 regulates spindle orientation by phosphorylating NuMA in human cells
Dohmen et al. AMPK-dependent activation of the Cyclin Y/CDK16 complex controls autophagy
Qian et al. CLSTN3β enforces adipocyte multilocularity to facilitate lipid utilization

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20171129